Earnings Ahead

GALT - Galectin Therapeutics, Inc.

1.415 0.095 7.2

  1. Home
  2. Healthcare
  3. GALT
Galectin Therapeutics, Inc.

Galectin Therapeutics, Inc.

About

Profile

Headquarters

Norcross, Georgia, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

GALT



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Galectin Therapeutics GAAP EPS of -$0.65 in-line
  • Galectin gets safety board nod to continue trial of liver disease drug belapectin
  • Galectin Therapeutics GAAP EPS of -$0.14
  • Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
  • Galectin Therapeutics GAAP EPS of -$0.16
  • Galectin Therapeutics GAAP EPS of -$0.17
  • Independent safety board recommends continuing Galectin's NAVIGATE trial without changes
  • Galectin Therapeutics GAAP EPS of -$0.52 beats by $0.07
  • Galectin Therapeutics EPS beats by $0.04
  • Galectin Therapeutics announces $20M convertible debt financing from its Chairman
  • Galectin Therapeutics expands NASH trial for Belapectin despite COVID-19 impact
  • Galectin Therapeutics EPS beats by $0.03
  • Allied Healthcare Products, SCWorx leads healthcare gainers; Meridian Bioscience, Aridis Pharmaceuticals among major losers
  • Galectin Therapeutics, ReShape Lifesciences leads healthcare gainers; Sigilon Therapeutics, Aerpio Pharmaceuticals among major losers
  • Galectin Therapeutics shares soar on early-stage Belapectin cancer study data
  • Bionano Genomics to join Russell 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks
  • Galectin Therapeutics EPS beats by $0.06
  • Galectin Therapeutics jumps 16%, world-renowned Dr. Ben Carson joins as special consultant
  • RIOT, MVIS, MSRT and FOLD among premarket gainers
  • Galectin's belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
November 16, 2021 - / -0.13 - / -
August 16, 2021 -0.15 / -0.13 - / -
May 17, 2021 -0.11 / -0.13 - / -
April 1, 2021 -0.14 / -0.12 - / -
November 10, 2020 - / -0.09 - / -
August 10, 2020 -0.11 / -0.07 - / -
May 11, 2020 -0.06 / -0.08 - / -
March 19, 2020 - / -0.06 - / -
November 12, 2019 -0.05 / -0.1 - / -
August 9, 2019 -0.06 / -0.12 - / -
May 10, 2019 -0.2 / -0.14 - / -
March 6, 2019 -0.08 / -0.08 - / 5M
November 13, 2018 -0.07 / -0.06 - / 5M
August 14, 2018 -0.11 / -0.1 - / -
March 26, 2018 - / -0.11 - / -
November 7, 2017 -0.13 / -0.14 - / -
August 14, 2017 -0.14 / -0.15 - / -
May 16, 2017 - / -0.1 - / -
March 28, 2017 -0.12 / -0.18 - / -
November 14, 2016 -0.19 / -0.22 - / -
Date Price Open High Low Vol Change ER
Aug 25 1.970 2.040
2.041
1.950
37.10K -3.43%
Aug 24 2.040 1.950
2.070
1.921
43.97K 2.51%
Aug 23 1.990 1.990
1.990
1.850
49.23K -0.5%
Aug 22 2.000 1.950
2.080
1.902
92.91K 0%
Aug 19 2.000 2.080
2.080
1.980
80.34K -4.31%
 
Aug 18 2.090 2.080
2.150
2.014
65.88K -0.48%
Aug 17 2.100 2.150
2.190
2.080
38.77K -3.67%
Aug 16 2.180 2.250
2.250
2.150
53.76K 0%
Aug 15 2.180 2.070
2.210
2.070
82.13K 5.31%
Aug 12 2.070 2.030
2.170
2.000
56.88K 1.97%
Aug 11 2.030 2.010
2.050
1.980
46.95K 1.25%
Aug 10 2.005 1.950
2.110
1.950
129.15K 4.97%